Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B‐cell Acute Lymphoblastic Leukemia

• Published in: HemaSphere 2022-03, Vol.6 (3), p.e701-n/a
• Main Authors: Hohtari, Helena, Kankainen, Matti, Adnan‐Awad, Shady, Yadav, Bhagwan, Potdar, Swapnil, Ianevski, Aleksandr, Dufva, Olli, Heckman, Caroline, Sexl, Veronika, Kytölä, Soili, Mustjoki, Satu, Porkka, Kimmo
• Format: Article
• Language: English
• ISSN: 2572-9241; 2572-9241
• DOI: 10.1097/HS9.0000000000000701

In adult patients, the treatment outcome of acute lymphoblastic leukemia (ALL) remains suboptimal. Here, we used an ex vivo drug testing platform and comprehensive molecular profiling to discover new drug candidates for B‐ALL. We analyzed sensitivity of 18 primary B‐ALL adult patient samples to 64 drugs in a physiological concentration range. Whole‐transcriptome sequencing and publicly available expression data were used to examine gene expression biomarkers for observed drug responses. Apoptotic modulators targeting BCL2 and MDM2 were highly effective. Philadelphia chromosome–negative (Ph–) samples were sensitive to both BCL2/BCL‐W/BCL‐XL‐targeting agent navitoclax and BCL2‐selective venetoclax, whereas Ph‐positive (Ph+) samples were more sensitive to navitoclax. Expression of BCL2 was downregulated and BCL‐W and BCL‐XL upregulated in Ph+ ALL compared with Ph– samples, providing elucidation for the observed difference in drug responses. A majority of the samples were sensitive to MDM2 inhibitor idasanutlin. The regulatory protein MDM2 suppresses the function of tumor suppressor p53, leading to impaired apoptosis. In B‐ALL, the expression of MDM2 was increased compared with other hematological malignancies. In B‐ALL cell lines, a combination of BCL2 and MDM2 inhibitor was synergistic. In summary, antiapoptotic proteins including BCL2 and MDM2 comprise promising targets for future drug studies in B‐ALL.